Abstract | BACKGROUND/AIMS: METHODOLOGY: Peripheral blood was collected prior to the test food ingestion and was incubated with fluorescein-labeled lentinan. The rates of lentinan-binding CD14+ monocytes were determined by flow cytometry. Patient survival times were followed up for 3 years. RESULTS: Thirty-six patients were eligible among 40 enrolled patients. Median survival time of eligible patients was 13.6 months (95% confidence interval, 8.7-18.9 months). Survival times of patients who ingested test food for a mean period of 47 weeks (range, 26 to 145 weeks) were significantly longer than that of patients who ingested for 7 to 12 weeks (p < 0.05). The rates of lentinan-binding cells in CD14+ monocytes showed individual variations (0.1-19.7%; Median, 1.6%). Survival times (median survival time, 16.3 months) of lentinan-high-binding group were significantly longer than those (median survival time, 12.5 months) of lentinan-low-binding group (p < 0.05). CONCLUSIONS: A superfine dispersed lentinan-containing supplementary food is effective for hepatocellular carcinoma patients' survival. Long-time ingestion is preferable. Assessment of lentinan-binding CD14+ monocytes is a promising prognostic predictor.
|
Authors | Norio Isoda, Yuichiro Eguchi, Haruhiko Nukaya, Keiko Hosho, Yasuyo Suga, Tetsuya Suga, Saburo Nakazawa, Kentaro Sugano |
Journal | Hepato-gastroenterology
(Hepatogastroenterology)
2009 Mar-Apr
Vol. 56
Issue 90
Pg. 437-41
ISSN: 0172-6390 [Print] Greece |
PMID | 19579616
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Lentinan
|
Topics |
- Administration, Oral
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Carcinoma, Hepatocellular
(drug therapy)
- Dietary Supplements
- Female
- Humans
- Lentinan
(administration & dosage, therapeutic use)
- Liver Neoplasms
(drug therapy)
- Male
- Middle Aged
- Survival Rate
- Treatment Outcome
|